Study on Tarlatamab for Treating Prostate Cancer

Inclusion Criteria

• Must be 18 years or older.
• Must have prostate cancer confirmed by lab tests.
• Cancer must have spread to other parts of the body, as shown by specific imaging tests.
• Must have low testosterone levels if receiving hormone therapy, unless diagnosed with a specific type of prostate cancer called small cell NEPC.
• Must have shown progression on at least one previous treatment for metastatic cancer.
• Must have DLL3 positive cancer, confirmed by a tumor biopsy.
• Must have normal organ function and acceptable blood test results.
• Must agree to use effective birth control during the study and for 60 days after the last dose of the study drug.

Exclusion Criteria

• Cannot have another type of cancer that could interfere with the study.
• Cannot have uncontrolled high blood pressure or recent major heart problems.
• Cannot have active hepatitis B or C, or HIV with a detectable viral load.
• Cannot have a history of certain lung diseases or autoimmune diseases requiring treatment in the past two years.
• Cannot have received certain treatments or medications close to the start of the study.
• Cannot have had major surgery recently or be using medications that could interact with the study drug.
• Cannot have an allergy to any of the study drugs.